Navigation Links
Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations
Date:5/15/2008

rtan component may occur after initiation of treatment with AZOR. Treatment should start under close medical supervision.

Vasodilation

Since the vasodilation attributable to amlodipine in AZOR is gradual in onset, acute hypotension has rarely been reported after oral administration. Nonetheless, caution, as with any other peripheral vasodilator, should be exercised when administering AZOR, particularly in patients with severe aortic stenosis.

Severe Obstructive Coronary Artery Disease

Patients, particularly those with severe obstructive coronary artery disease, may develop increased frequency, duration, or severity of angina or acute myocardial infarction on starting calcium channel blocker therapy or at the time of dosage increase.

Congestive Heart Failure

In general, calcium channel blockers should be used with caution in patients with heart failure.

Impaired Renal Function

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. There has been no long-term use of olmesartan medoxomil in patients with unilateral or bilateral renal artery stenosis, but similar effects would be expected with AZOR because of the olmesartan medoxomil component.

Hepatic Impairment

Since amlodipine is extensively metabolized by the liver and the plasma elimination half-life (t1/2) is 56 hours in patients with severely impaired hepatic function, caution should be exercised when administering AZOR to patients with severe hepatic impairment.

Laboratory Tests

There was a greater decrease in hemoglobin and hematocrit in the combination product compared to either component alone.

Adverse Reactions

The only adverse reaction that occurred in greater than or equal to 3% of patients treated with AZOR and more frequently than placebo was edema. The placebo-subtracted incidence was 5.7% (5
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
3. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
4. Recent Studies Suggest Popular Diet Pill Relacore Reduces Acne Breakouts
5. Minimally Invasive Treatment Reduces Shoulder Pain From Tendonitis
6. Smokefree Workplace Law Reduces Heart Attacks 59% Among Nonsmokers, New Research Shows
7. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
8. CV Therapeutics Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
9. VIA Pharmaceuticals Presents Data at American Heart Association Meeting Showing VIA-2291 Significantly Reduces Inflammation in Preclinical Model of Atherosclerosis
10. Study Finds Starion Instruments Tissue Welding Technology Reduces Pain and Bleeding in Tonsillectomy Patients
11. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014  BioScrip ® , Inc. (NASDAQ: BIOS ) ... Executive Officer, will present at the Bank of America Merrill Lynch ... , Date: , , , Wednesday, December 3, 2014 , ... , , , Location: , , , Boca Raton Resort ... Inc. BioScrip, Inc. is a leading national ...
(Date:11/26/2014)... -- Zynerba Pharmaceuticals , Inc., a specialty pharmaceutical ... cannabinoid treatments, today announced that the company will present ... The conference will be held December 2 to 3, ... York . Zynerba,s Chairman and CEO, Armando ... December 2. To listen to a webcast ...
(Date:11/26/2014)... 26, 2014  Aridis Pharmaceuticals, Inc., a biopharmaceutical ... for infectious diseases, announced today the addition of ... key opinion leader in the areas of pneumonia ... Founder and Chief Executive Officer, ... Opal,s extensive experience investigating bacterial toxins and key ...
Breaking Medicine Technology:Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3
... Pharmaceuticals, Inc., a privately held drug development company, is ... as Executive Chairman of the Board of Directors. ... important milestone for Tigris Pharmaceuticals, future," said Edmundo Muniz, ... brings to Tigris extraordinary ability and pharmaceutical industry experience ...
... Sept. 28 Sunridge International (OTC Bulletin Board: ... glaucoma and ocular hypertension will be introduced in October ... Presentations have been planned by its Indian ... October 1 – 14.  The company,s Pneumatic Trabeculoplasty (PNT), ...
Cached Medicine Technology:Tigris Pharmaceuticals Appoints Neil Flanzraich to Executive Chairman of the Board 2Tigris Pharmaceuticals Appoints Neil Flanzraich to Executive Chairman of the Board 3Sunridge to Introduce Their PNT Treatment for Glaucoma to Medical Personnel in India 2
(Date:11/26/2014)... The family foundation of Best Buy founder, Richard ... Foundation (Meso Foundation), half of which will be specifically ... Program . The focus area of the Richard M. ... organizations that can generate transformational results in education, human ... and chairman emeritus of Best Buy Co., Inc., the ...
(Date:11/26/2014)... Arlington, VA (PRWEB) November 26, 2014 ... Ushma Suvarnakar as the Association’s new director of ... directing the Association’s annual meeting, special events and ... Ushma Suvarnakar to this post,” said AAA Executive ... contagious level of enthusiasm and energy. She was ...
(Date:11/26/2014)... For its December issue , Atlantic Information ... Blue Cross and Blue Shield Plans* interviewed officials at ... the two Blues plans are implementing in order to ... apnea, ranging from brick-and-mortar retail stores to patient data ... rates of a variety of serious disorders, including hypertension, ...
(Date:11/26/2014)... GI for Life announced today, that they ... of their popular nutritional supplements: ColoVite Colon Health ... Discounts of 40% will be offered for a limited ... ColoVite supplement is a scientifically formulated vitamin supplement developed ... easy-to-take colon vitamin with ALL the nutrients associated with ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 Anthropologists ... effectiveness in containing and stopping Ebola, improve international ... in healthcare systems in West Africa. , ... to Stop Ebola: Anthropologists Offer Insights,” will be ... the American Anthropological Association (AAA), Fri., Dec. 5, ...
Breaking Medicine News(10 mins):Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 2Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 3Health News:American Anthropological Association Appoints New Director of Meetings and Conferences: Ushma Suvarnakar 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 3Health News:GI For Life Slashes Prices by 40% on Liposomal Vitamin D3 and ColoVite Colon Health Formula for a Limited Time 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 3
... developed a fertility predictor test, which enables women to ... or decreasing. This will be particularly useful to women ... best age for child bearing is// reported to be ... of the Sheffield University. But the pressure of modern ...
... School is exploring the beneficial properties of Lactic acid ... is used for fermentation of curd and yogurt, used ... also as applications in saving fish culture system from ... inhibit the binding of HIV virus into the mucous ...
... over safety with regard to the hormone replacement therapy (HRT), another ... from diseases related to the heart. //The risk of a coronary ... who start with the HRT at an younger age, when in ... ,There are no cardiovascular benefits to be seen in the case ...
... Washington University School of Medicine identify yet another reason to ... been found to play a critical role in the development// ... diet have been found to have a low bone mass. ... 18 individuals aged between 33 and 85 years, under a ...
... themselves to come out of the financial crisis they ... British Health secretary as welcomed better financial management ... cutting unnecessary fund wastage. ,The health ... the NHS hospitals will be followed and finance management ...
... gave the all clear to 21 women who had breast ... chances of fighting and surviving the disease//. ,It ... years after she was given a clean chit by the ... Manchester. The said radiologist worked at Trafford General and the ...
Cached Medicine News:Health News:Raw Vegan Diet Promises Lightweight, Healthy Bones 2
The 96 PW is an intelligent full microplate washer with a 96 needle wash head washing all wells simultaneously. This instrument gives high throughput and outstanding washing efficiency....
Stat Fax 2600 is fully automatic microplate washer....
... 1575 immunowash microplate washer ... needle position to perform ... maximize wash efficiency. This ... choice of wash that ...
... LMW Automated Microplate ... choice for any laboratory. ... sensor allows a precise ... residual volume, digitally controlled ...
Medicine Products: